Results 71 to 80 of about 1,923,383 (256)

Size-dependent activation of chimeric antigen receptor (CAR)-T cells

Science immunology, 2022
As the targets of chimeric antigen receptor (CAR)–T cells expand to a variety of cancers, autoimmune diseases, viral infections, and fibrosis, there is an increasing demand for identifying new antigens and designing new CARs that can be effectively ...
Qian Xiao, Xin-Yan Zhang, Liqun Tu, Jian Cao, C. Hinrichs, Xiao-Lei Su   +5 more
semanticscholar   +1 more source

Chimeric Antigen Receptor T Cell Therapy: A Review [PDF]

, 2018
Chimeric Antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). CARs are engineered and constructed specifically to reprogram a
Knouse, Michael
core   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer

JAMA Oncology
Key Points Question Can chimeric antigen receptor T-cell therapy (CART) change the therapeutic landscape of advanced colorectal and other solid cancers akin to its effects in the hematologic cancers?
N. Chen, Chengfei Pu, Lingling Zhao, Wei Li, Chang Wang, R. Zhu, Tingting Liang, Chao Niu, Xi Huang, Hai-Yang Tang, Yizhuo Wang, Hang Yang, B. Jia, Xianyang Jiang, Guiting Han, Wensheng Wang, Dongqi Chen, Yi-Ming Wang, Eric Rowinsky, E. Kennedy, V. Lu, Guozhen Cui, Zhao Wu, Lei Xiao, Jiu-Wei Cui   +24 more
semanticscholar   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities

Intensive Care Medicine
The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies.
Torsten Schroeder, Tjark Martens, L. Fransecky, T. Valerius, N. Schub, C. Pott, C. Baldus, F. Stölzel   +7 more
semanticscholar   +1 more source

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa, Katsuaki Imaizumi, Shinichi Makita, Kensei Tobinai   +3 more
core   +1 more source

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma [PDF]

, 2019
After unprecedented successes in B-cell malignancies, chimeric antigen receptor T cells have recently been investigated for the treatment of multiple myeloma.
Maguire, T., Lichtman, E., McKay, K., Sun, C., Ballard, B., Ramos, C., West, J., Dotti, G., Kale, B., Mahendravada, A., Savoldo, B., Tuchman, S.   +11 more
core   +1 more source

CD4+ chimeric antigen receptor T cells in for the long journey

, 2022
In a recently published article, Melenhorst et al. performed a longitudinal analysis on chimeric antigen receptor (CAR) T cells isolated from patients over 10 years after therapy, revealing expansion of a long-lived CD4+ CAR T-cell population with a ...
Beavis, PA, Chen, AXY, House, IG, Derrick, EB   +3 more
core   +1 more source

convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting [PDF]

, 2020
We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of traditional CAR therapies. An inert form of the human NKG2D extracellular domain (iNKG2D) was engineered as the ectodomain of the ...
Roybal, Kole T, Williams, Steven R, Steiger, Daniel, Lok, Stephen, Landgraf, Kyle E, Gebhart, Dana, Martin, David W, Kim, Kaman Chan   +7 more
core   +1 more source